You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)
|
|---|---|
| Published in |
Respiratory Research, June 2017
|
| DOI | 10.1186/s12931-017-0609-7 |
| Pubmed ID | |
| Authors |
Sean Duffy, Robert Marron, Helen Voelker, Richard Albert, John Connett, William Bailey, Richard Casaburi, J. Allen Cooper, Jeffrey L. Curtis, Mark Dransfield, MeiLan K. Han, Barry Make, Nathaniel Marchetti, Fernando Martinez, Stephen Lazarus, Dennis Niewoehner, Paul D. Scanlon, Frank Sciurba, Steven Scharf, Robert M. Reed, George Washko, Prescott Woodruff, Charlene McEvoy, Shawn Aaron, Don Sin, Gerard J. Criner, the NIH COPD Clinical Research Network and the Canadian Institutes of Health Research |
| Abstract |
Beta-blockers are commonly prescribed for patients with cardiovascular disease. Providers have been wary of treating chronic obstructive pulmonary disease (COPD) patients with beta-blockers due to concern for bronchospasm, but retrospective studies have shown that cardio-selective beta-blockers are safe in COPD and possibly beneficial. However, these benefits may reflect symptom improvements due to the cardiac effects of the medication. The purpose of this study is to evaluate associations between beta-blocker use and both exacerbation rates and longitudinal measures of lung function in two well-characterized COPD cohorts. We retrospectively analyzed 1219 participants with over 180 days of follow up from the STATCOPE trial, which excluded most cardiac comorbidities, and from the placebo arm of the MACRO trial. Primary endpoints were exacerbation rates per person-year and change in spirometry over time in association with beta blocker use. Overall 13.9% (170/1219) of participants reported taking beta-blockers at enrollment. We found no statistically significant differences in exacerbation rates with respect to beta-blocker use regardless of the prevalence of cardiac comorbidities. In the MACRO cohort, patients taking beta-blockers had an exacerbation rate of 1.72/person-year versus a rate of 1.71/person-year in patients not taking beta-blockers. In the STATCOPE cohort, patients taking beta-blockers had an exacerbation rate of 1.14/person-year. Patients without beta-blockers had an exacerbation rate of 1.34/person-year. We found no detrimental effect of beta blockers with respect to change in lung function over time. We found no evidence that beta-blocker use was unsafe or associated with worse pulmonary outcomes in study participants with moderate to severe COPD. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 21% |
| United States | 2 | 14% |
| Japan | 1 | 7% |
| Colombia | 1 | 7% |
| India | 1 | 7% |
| Canada | 1 | 7% |
| Germany | 1 | 7% |
| Unknown | 4 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 71% |
| Practitioners (doctors, other healthcare professionals) | 4 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 14% |
| Researcher | 8 | 12% |
| Other | 7 | 11% |
| Student > Doctoral Student | 6 | 9% |
| Student > Master | 6 | 9% |
| Other | 9 | 14% |
| Unknown | 20 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 17% |
| Nursing and Health Professions | 2 | 3% |
| Social Sciences | 2 | 3% |
| Computer Science | 1 | 2% |
| Other | 5 | 8% |
| Unknown | 24 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2018.
All research outputs
#1,493,205
of 25,382,440 outputs
Outputs from Respiratory Research
#120
of 3,062 outputs
Outputs of similar age
#29,378
of 329,774 outputs
Outputs of similar age from Respiratory Research
#7
of 65 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,062 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.